ライフサイエンスコーパス: withdrawal symptom

1 ge, 0-51; higher scores indicate more severe withdrawal symptoms).

2 ptor subunits expressed therein, in nicotine withdrawal symptoms.

3 ntial therapeutic agents in treating alcohol withdrawal symptoms.

4 eceptor-facilitating agents suppress alcohol withdrawal symptoms.

5 line receptors in the appearance of nicotine withdrawal symptoms.

6 abuse and the manifestations of opiate/drug withdrawal symptoms.

7 caine-dependent patients with severe cocaine withdrawal symptoms.

8 n heart rate (HR), and characteristic opiate withdrawal symptoms.

9 ed in an even more impressive suppression of withdrawal symptoms.

10 vely reduced the expression of certain other withdrawal symptoms.

11 nergic neurons in the expression of morphine withdrawal symptoms.

12 3alpha, 5alpha-THP) that produces anxiogenic withdrawal symptoms.

13 actice of drug holidays and reports of acute withdrawal symptoms.

14 epines and ethanol can also produce PMS-like withdrawal symptoms.

15 n to decrease the expression of precipitated withdrawal symptoms.

16 sed to underlie the manifestation of ethanol withdrawal symptoms.

17 s constipation, and mitigates chronic opioid withdrawal symptoms.

18 ine anticipatory behavior and reduces opioid withdrawal symptoms.

19 ct at receptors by fixed amounts to minimise withdrawal symptoms.

20 pain reliever and for attenuation of opioid withdrawal symptoms.

21 role in many behaviors related to human THC withdrawal symptoms.

22 d escalation of ethanol drinking and somatic withdrawal symptoms.

23 doses have shown greater success in reducing withdrawal symptoms.

24 tisfy smokers and alleviate nicotine-related withdrawal symptoms.

25 uggests that the ACC is a locus for multiple withdrawal symptoms.

26 tions between intra-individual glutamate and withdrawal symptoms.

27 gimens for other medications associated with withdrawal symptoms.

28 icipants) reported antidepressant-associated withdrawal symptoms.

29 id-mediated effects, including analgesia and withdrawal symptoms.

30 of tramadol ER as a method to manage opioid withdrawal symptoms.

31 ne was released in the vBNST during specific withdrawal symptoms.

32 ics of intoxication or by characteristics of withdrawal symptoms.

33 se synapses and robustly suppresses morphine withdrawal symptoms.

34 716 significantly attenuated somatic alcohol withdrawal symptoms.

35 ve therapy for up to 5 days or resolution of withdrawal symptoms.

36 er was correlated with decreased craving and withdrawal symptoms.

37 on of pleasure from cigarettes and relief of withdrawal symptoms.

38 may contribute to amelioration of subjective withdrawal symptoms.

39 ues, and both decreasing dACC GABA and early withdrawal symptoms.

40 because of its association with less severe withdrawal symptoms.

41 duced IPN neuronal activation and alleviated withdrawal symptoms.

42 the thalamus and brainstem without reducing withdrawal symptoms.

43 low-dose varenicline, significantly reduced withdrawal symptoms.

44 bserved in those reporting low or no alcohol withdrawal symptoms.

45 ence, medication diversion, and emergence of withdrawal symptoms.

46 the intensity of running and the severity of withdrawal symptoms.

47 lcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial.

48 Among participants without withdrawal symptoms, abstinence rates were higher over t

49 harmacological approach to mitigating opioid withdrawal symptoms across sexes, potentially through mo

50 we show that induction of physical nicotine withdrawal symptoms activates GABAergic neurons within t

51 As in humans, rodents undergo physical withdrawal symptoms after cessation from chronic nicotin

52 t presented twice with toxic effects and had withdrawal symptoms after her second presentation.

53 Stronger nicotine withdrawal symptoms among the depressed smokers contribu

54 ion is strongly influenced by a reduction in withdrawal symptoms, an expectation of stress reduction,

55 lone administration would decrease marijuana withdrawal symptoms and a laboratory measure of marijuan

56 e produced a robust attenuation of marijuana withdrawal symptoms and a laboratory measure of relapse

57 ents of cigarette smoke significantly impact withdrawal symptoms and associated brain areas, independ

58 eavy use increases the likelihood of alcohol withdrawal symptoms and associated secondary outcomes of

59 and buprenorphine act by suppressing opioid withdrawal symptoms and attenuating the effects of other

60 ficacy (tolerance), as well as physiological withdrawal symptoms and behavioral manifestations such a

61 45, a novel FAAH inhibitor, reduced cannabis withdrawal symptoms and cannabis use in men, and might r

62 and function, playing a crucial role in EtOH withdrawal symptoms and dependence.

63 ve treatments merit exploration for reducing withdrawal symptoms and drinking in alcohol-dependent in

64 lower abuse liability and induced relief of withdrawal symptoms and drug cravings, despite acting on

65 rticipants in both groups reported relief of withdrawal symptoms and drug-related human immunodeficie

66 erneurons, may be beneficial for alleviating withdrawal symptoms and facilitating smoking cessation.

67 of varenicline for managing global nicotine withdrawal symptoms and for smoking cessation, its effec

68 eking cohort, nabiximols attenuated cannabis withdrawal symptoms and improved patient retention in tr

69 ectiveness of amantadine in reducing cocaine withdrawal symptoms and improving treatment outcome amon

70 Improvements in antidepressant withdrawal symptoms and mental well-being were also smal

71 jects with the highest scores on measures of withdrawal symptoms and of addiction severity that have

72 demonstrated efficacy in mitigating alcohol withdrawal symptoms and preventing relapse drinking in i

73 en or are being developed to relieve smoking withdrawal symptoms and promote abstinence from smoking.

74 aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding propertie

75 ncing the methadone dose required to prevent withdrawal symptoms and relapse in this population.

76 ent treatments rely on suppressing immediate withdrawal symptoms and replacing illicit drug use with

77 ation and nicotine on suppression of tobacco withdrawal symptoms and smoking behavior.

78 f directly translatable non-precipitated THC withdrawal symptoms and the neural mechanisms that affec

79 ate drug (that is, without relapse or severe withdrawal symptoms) and clinical outcomes (neuropsychia

80 studies just provided incidence of specific withdrawal symptoms, and 4 studies only described other

81 ithdrawal (group 1), 51.3% of whom evidenced withdrawal symptoms, and 446 subjects (13.1%) without a

82 d significant decreases in illicit drug use, withdrawal symptoms, and depression.

83 ic CBD administration on alcohol dependence, withdrawal symptoms, and neurodegeneration using two com

84 The findings indicate that alcohol withdrawal symptoms are a significant moderator of prazo

85 Alcohol craving, addiction, and withdrawal symptoms are affected by serotonin concentrat

86 ally assessed how behaviors that model human withdrawal symptoms are altered by chronic THC treatment

87 Although withdrawal symptoms are commonly reported by persons see

88 Withdrawal symptoms are observed upon cessation of canna

89 that drug pleasure and subsequent unpleasant withdrawal symptoms are the chief causes of addiction; (

90 the mechanism and neuroanatomical bases for withdrawal symptoms are unclear.

91 e data support further evaluation of alcohol withdrawal symptoms as a prognostic indicator of prazosi

92 rview (p=0.004), and significantly decreased withdrawal symptoms as measured by the Marijuana Withdra

93 dence (N=100) with varying levels of alcohol withdrawal symptoms assessed at treatment entry.

94 ment, pregabalin does not appear to have the withdrawal symptoms associated with the benzodiazepines.

95 ter the brain prevents the sudden and severe withdrawal symptoms associated with therapeutics that ta

96 ime to relapse (P = 0.0002) and an impact on withdrawal symptoms at target quit date (TQD) (P = 0.000

97 Among subjects with severe cocaine withdrawal symptoms at the start of treatment, those who

98 he six subjects experienced mild to moderate withdrawal symptoms between the third and fifth days of

99 t cigarette and the urge to smoke to relieve withdrawal symptoms but not the severity of nicotine dep

100 enula are key mediators of aversive nicotine withdrawal symptoms, but the downstream neural targets m

101 Nicotine withdrawal symptoms can also be observed in rodents.

102 ealthy behaviours, detoxification to address withdrawal symptoms, cognitive-behavioural therapies to

103 Withdrawal symptoms complicated conversion from predniso

104 Nicotine withdrawal symptoms contribute to relapse in smokers, th

105 Both norepinephrine and withdrawal symptoms could be elicited in the absence of

106 elapse to smoking was predicted by increased withdrawal symptoms, decreased left DLPFC and increased

107 eceptor occupancy by varenicline and tobacco withdrawal symptoms ((*)denoting other putative nAChR su

108 The expression of somatic withdrawal symptoms depends mainly on the alpha5, alpha2

109 companied by a threefold reduction in opiate withdrawal symptoms despite normal antinociceptive toler

110 to manage a range of comorbid conditions and withdrawal symptoms, despite a lack of evidence.

111 Patients with stronger withdrawal symptoms displayed the largest volume increas

112 mparable to buprenorphine in reducing opioid withdrawal symptoms during a residential tapering progra

113 s the dopaminergic reward system by reducing withdrawal symptoms during abstinence and by decreasing

114 lcohol self-administration and physiological withdrawal symptoms during acute withdrawal and protract

115 re treatment-related differences in cannabis withdrawal symptoms during hospital admission, and week

116 withdrawal phenomena, reduction in nicotine withdrawal symptoms during smoking cessation, analgesia,

117 tive food-restricted rats displayed the most withdrawal symptoms, followed by active rats given 24-hr

118 drugs can lead to dependence as indicated by withdrawal symptoms following cessation and tolerance to

119 alities are often a prominent contributor to withdrawal symptoms following chronic drug use.

120 Although animal studies have examined withdrawal symptoms following exposure to delta-9-tetrah

121 assess the addictive potential of exercise, withdrawal symptoms following injections of 1.0 mg/kg na

122 (72 hr) of withdrawal, even though physical withdrawal symptoms had resolved at this time point.

123 rated (P <.001) and patient-rated (P = .004) withdrawal symptoms, had lower patient ratings of cravin

124 Drug administration to avoid unpleasant drug withdrawal symptoms has been hypothesized to be a crucia

125 Discontinuation induced withdrawal symptoms have been reported for almost all an

126 as not associated with tolerance, reward, or withdrawal symptoms, highlighting its potential clinical

127 Increased anxiety is a prominent withdrawal symptom in abstinent smokers, yet the neuroan

128 lation of channelrhodopsin elicited physical withdrawal symptoms in both nicotine-naive and chronic-n

129 of the potassium channel Kir2.1, attenuated withdrawal symptoms in fentanyl-dependent mice.

130 ed a marked reduction in fentanyl choice and withdrawal symptoms in fentanyl-dependent rats.

131 ecommend a pharmacologic regimen titrated to withdrawal symptoms in ICU patients with alcohol withdra

132 en under elevated pressure, reduced physical withdrawal symptoms in morphine-dependent male mice.

133 cohol self-administration from physiological withdrawal symptoms in relation to KOR signaling in the

134 r brain-based therapies seeking to attenuate withdrawal symptoms in the critical early stages of smok

135 Risk factors for withdrawal symptoms included being female, younger, expe

136 om alcohol addiction or abuse is hampered by withdrawal symptoms including severe headaches, which of

137 Nevertheless, nicotine-withdrawal symptoms, including depressed mood, anxiety,

138 A history of major depression and persistent withdrawal symptoms independently predicted posttreatmen

139 measure anxiety-like behavior, an affective withdrawal symptom, IPN GABAergic neuron activity was in

140 o chronic ethanol consumption that underlies withdrawal symptoms, is thought to directly contribute t

141 Retention, withdrawal symptom management, concomitant medication ut

142 was negatively correlated with the change in withdrawal symptom manifestations as measured by the Wis

143 In fact, withdrawal symptoms may be present, and the prognosis of

144 t is thought that the modulation of nicotine withdrawal symptoms may contribute to their effectivenes

145 on, anxiety, quality of life, antidepressant withdrawal symptoms, mental well-being, enablement, sati

146 The authors examined whether alcohol withdrawal symptoms moderate the efficacy of prazosin in

147 ng effects of a drug and the desire to avoid withdrawal symptoms motivate continued drug use, and the

148 Individuals with high alcohol withdrawal symptoms on prazosin compared with placebo al

149 By week 12, participants with high alcohol withdrawal symptoms on prazosin reported 7.07% heavy dri

150 The time course of withdrawal symptom onset and the rationale for drug holi

151 uding voluntary ethanol consumption, ethanol withdrawal symptoms, operant ethanol self-administration

152 Although no physical withdrawal symptoms or alterations in the plasma cortico

153 FR) did not alter the acquisition of somatic withdrawal symptoms or escalation of ethanol drinking in

154 Some withdrawal symptoms or relapses may have been missed.

155 No loss of consciousness, withdrawal symptoms, or increased suicidal ideation or b

156 e ICU Severity Scale, and Sophia Observation Withdrawal Symptoms Pediatric Delirium scale), identify

157 he role of this pathway in mediating ethanol withdrawal symptoms (physical dependence).

158 epressive and anxiety symptoms, physical and withdrawal symptoms, quality of life, time to stopping a

159 42 = -0.32, P < .05) and more severe alcohol-withdrawal symptoms (r38 = -0.35, P < .05).

160 cits in learning, are one of the most common withdrawal symptoms reported by smokers.

161 ads the occurrence of physical and affective withdrawal symptoms representing a major burden to quit

162 n addict to escape from and avoid the severe withdrawal symptoms resulting from opiate dependence.

163 ovement), and Michelson SSRI (Selective SRI) Withdrawal Symptoms Scale scores (range, 0-51; higher sc

164 es in symptomatic days or the Michelson SSRI Withdrawal Symptoms Scale.

165 Sertraline treatment produced a lower total withdrawal symptom score and less irritability, anxiety,

166 dicated a significant interaction of alcohol withdrawal symptom score by treatment by full-dose treat

167 However, abstinence was moderated by withdrawal symptom severity (odds ratio=0.95, 95% CI=0.9

168 of life; moderators were MOUD type, gender, withdrawal symptom severity, pain severity, and loneline

169 d repeated self-report measures (ie, tobacco withdrawal symptoms, smoking urge, and negative affect (

170 severity, function, quality of life, opioid withdrawal symptoms, substance use, and adverse events.

171 Smoking cessation results in withdrawal symptoms such as craving and negative mood th

172 ine users, which might contribute to cocaine withdrawal symptoms such as depression and suicidality.

173 sm requires the proper management of ethanol withdrawal symptoms, such as anxiety, to prevent further

174 rthermore, NFP produced significantly lesser withdrawal symptoms than naloxone at similar doses.

175 It also produced less severe opioid withdrawal symptoms than naloxone in morphine-dependent

176 antagonists in vivo with significantly fewer withdrawal symptoms than naloxone observed at similar do

177 gonists might be useful for the treatment of withdrawal symptoms that contribute to the maintenance o

178 onomic output underlies many of the aversive withdrawal symptoms that make it difficult to discontinu

179 rug-associated cues can elicit the emotional withdrawal symptoms that promote cocaine use.

180 is generally directed at the suppression of withdrawal symptoms through maintenance of the 'addicted

181 evelopment of tolerance and the emergence of withdrawal symptoms upon cessation of chronic nicotine a

182 Psychiatric evaluation to assess withdrawal symptoms was also done at each scanning sessi

183 .05; P < .001 for all), although duration of withdrawal symptoms was greater at higher doses (eta2 =

184 Subjective measures of smoking withdrawal symptoms were also collected.

185 Cannabis withdrawal symptoms were assessed using the Marijuana Wi

186 phy device and wrist-worn actigraphy; opioid withdrawal symptoms were assessed via the Subjective Opi

187 oral-cecal transit time, and central opioid withdrawal symptoms were compared between the 2 groups.

188 162) on voluntary ethanol intake and ethanol withdrawal symptoms were evaluated in rats voluntarily c

189 cy for smoking abstinence and its effects on withdrawal symptoms were evaluated.

190 and other characteristics of antidepressant withdrawal symptoms were included.

191 reased mRNA expression and the appearance of withdrawal symptoms were inhibited.

192 In the intervention arm, antidepressant withdrawal symptoms were less severe, and mental well-be

193 ooled estimate was robust regardless whether withdrawal symptoms were measured in RCTs or observation

194 Only minimal withdrawal symptoms were observed in inactive rats.

195 No withdrawal symptoms were reported after treatment discon

196 tive components of naloxone-induced morphine withdrawal symptoms were significantly attenuated in M5-

197 y (urine toxicology, retention, craving, and withdrawal symptoms) were examined at the study midpoint

198 AEs), including investigator-assessed opioid withdrawal symptoms, were reported.

199 pically sudden onset, severe, and protracted withdrawal symptoms when medication was stopped.

200 lleviating incisional pain and narcotic drug withdrawal symptoms, which are now in clinical trials.

201 Withdrawal symptoms will then be minimised.

202 investigate the effect of MT-7716 on alcohol withdrawal symptoms, Wistar rats were withdrawn from a 7

203 rs, there is evidence for the association of withdrawal symptoms with MDMA abstinence.

204 ful attempts to cut down use, tolerance, and withdrawal symptoms), with ORs ranging between 1.6 (95%

205 binol (THC; dronabinol), decreases marijuana withdrawal symptoms, yet does not decrease marijuana use